export default function ZiconotideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Ziconotide (Prialt) is a synthetic version of a peptide toxin from the cone snail, FDA-approved for severe chronic pain that hasn&rsquo;t responded to other treatments. It only works when injected directly into the cerebrospinal fluid through a surgically implanted pump — not intravenously, not subcutaneously, not in any other way. This is not a community peptide. If you are here while considering self-administration, the answer is an unambiguous no.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Chronic Pain Patient &mdash; Exploring Options for Refractory Pain</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have severe chronic pain that hasn&rsquo;t responded to opioids or other treatments. My pain specialist mentioned ziconotide as an option. What is this and how does it work?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it&rsquo;s being considered</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It works through a completely different mechanism than opioids</strong><br />Ziconotide blocks a specific type of calcium channel (N-type) at pain-transmitting synapses in the spinal cord, preventing pain signals from being sent toward the brain. It has no activity at opioid receptors — which means it doesn&rsquo;t cause opioid dependence, tolerance, or respiratory depression. For patients who have exhausted opioid options or can&rsquo;t tolerate them, that non-opioid mechanism is genuinely meaningful.</li>
          <li><strong>It&rsquo;s FDA-approved for severe, refractory chronic pain specifically</strong><br />The approval covers conditions like cancer pain, failed back surgery syndrome, and complex regional pain syndrome — cases where other treatments have failed and the pain is severe enough to justify a surgically implanted spinal pump. That regulatory status means real clinical trial evidence supports its use in exactly that situation.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Ziconotide is not a first-line or easy treatment. It requires a surgically implanted intrathecal drug delivery system — a pump and catheter placed under general anesthesia by a neurosurgeon or pain specialist. Side effects are significant and include serious psychiatric effects (hallucinations, mood changes, cognitive impairment) that occur because the drug is delivered directly to the central nervous system. Dose titration is slow and careful, managed by the pain specialist through periodic pump refills. This is a specialist intervention for the most severe, treatment-resistant pain — not an option for people with moderate pain or those who haven&rsquo;t exhausted other treatments first. Net: genuinely effective for its specific indicated population, but the delivery system and neurological side effects mean it is reserved for cases where other options have failed.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Curious Person &mdash; Intrigued by the Cone Snail Origin</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve read that ziconotide comes from a cone snail toxin. It&rsquo;s showing up in peptide discussions. Is this something people actually use, or is it just a pharmacological curiosity?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why it shows up in peptide discussions</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The cone snail origin is genuinely fascinating pharmacological history</strong><br />Conus magus produces a venom peptide called omega-conotoxin MVIIA that evolved to paralyze fish for capture. Researchers recognized that this venom&rsquo;s calcium channel blocking mechanism could be refined into a pain drug — ziconotide is the synthetic version of that toxin, engineered for clinical use. It&rsquo;s one of the more compelling examples of discovering medicine in nature&rsquo;s arsenal of chemical weapons.</li>
          <li><strong>The mechanism is scientifically distinct from every other pain compound</strong><br />Calcium channel blockers for pain is a fundamentally different approach than opioids, NSAIDs, anticonvulsants, or antidepressants used for chronic pain. Ziconotide&rsquo;s N-type calcium channel specificity in spinal pain transmission is a precise, well-characterized mechanism that makes it interesting to anyone who follows pain neuroscience.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Ziconotide appearing in peptide community discussions reflects a misunderstanding about what the compound is. It shares the label &ldquo;peptide&rdquo; with BPC-157 and TB-500 in the technical sense — it&rsquo;s a chain of amino acids — but it is in no way comparable as a compound class, access route, or use case. Any route of administration other than intrathecal delivery would activate calcium channels throughout the body including cardiac muscle and autonomic neurons, producing severe and potentially fatal effects. There is no gray-market version, no subcutaneous protocol, no community use. Net: fascinating pharmacology and natural origin story, but it belongs on a reference page, not in a discussion of self-administered peptides.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; Pain Neuroscience and Calcium Channel Biology</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;The N-type calcium channel mechanism in spinal pain transmission is genuinely interesting neuroscience. What does ziconotide tell us about pain biology and the calcium channel axis that other compounds don&rsquo;t reach?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re interested</p>
        <ol className="reta-overview__profile-why">
          <li><strong>N-type calcium channels are specifically expressed at pain-transmitting presynaptic terminals</strong><br />The reason ziconotide has to be delivered intrathecally is that the N-type calcium channels it targets are concentrated at presynaptic terminals in the dorsal horn of the spinal cord. This anatomical specificity is actually the safety mechanism — peripheral calcium channels throughout the cardiovascular and nervous system would be dangerously affected by systemic delivery. The target specificity only works when you deliver the drug to where the target is concentrated.</li>
          <li><strong>The conotoxin pharmacological tradition has produced multiple research compounds</strong><br />The cone snail venom library has yielded not just ziconotide but a range of conotoxins targeting different ion channel subtypes — sodium, calcium, potassium, nicotinic acetylcholine receptors. This is an active area of ion channel pharmacology with implications for pain, cardiovascular, and neurological research well beyond ziconotide specifically.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Ziconotide is a reference compound for pain neuroscience education — it defines what a specific calcium channel target at spinal pain synapses can achieve. But it has no application outside the clinical intrathecal delivery context. The psychiatric side effects (hallucinations, mood changes, cognitive impairment) occurring even with spinal delivery reflect how deeply VGCCs are integrated into CNS function — the drug can&rsquo;t perfectly confine its effects to pain synapses even when delivered directly to the spinal fluid. Understanding ziconotide&rsquo;s mechanism clarifies why opioid-independent pain control is possible, why the intrathecal route exists, and what the limits of spinal-targeted pharmacology are. Net: essential pharmacological reference for pain neuroscience understanding, with no practical self-administration path or community use case.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Ziconotide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A community peptide in any sense — there is no self-administration route, no gray-market supply, no subcutaneous protocol</li>
              <li>Safe by any route other than intrathecal delivery — systemic administration would activate calcium channels throughout the body with severe and potentially fatal consequences</li>
              <li>Comparable to other peptides in the community space despite being a peptide chemically</li>
              <li>A first-line pain treatment — it is reserved for the most severe refractory chronic pain after other options have failed</li>
              <li>Easy or convenient — it requires surgically implanted intrathecal pump hardware and ongoing specialist management</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>Derived from cone snail venom — one of the more compelling examples of discovering medicine in nature&rsquo;s chemical weapons</li>
              <li>The only non-opioid drug that works through N-type calcium channel blockade at spinal pain synapses</li>
              <li>FDA-approved for severe refractory chronic pain with no opioid receptor activity — meaningful for opioid-intolerant patients</li>
              <li>Defines what spinal-targeted calcium channel pharmacology can achieve — important reference for pain neuroscience</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
